恩华药业(002262.SZ)：盐酸羟考酮缓释片获得《药品注册证书》

Core Viewpoint - Enhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of Oxycodone Hydrochloride Controlled-Release Tablets, a self-developed product aimed at enhancing the safety of opioid medication while ensuring therapeutic efficacy [1] Group 1: Product Development - The Oxycodone Hydrochloride Controlled-Release Tablets utilize physical-chemical barrier technology to achieve abuse-deterrent effects for oral opioid medications [1] - This formulation is intended for patients requiring long-term, scheduled opioid treatment for severe pain, where alternative treatments (such as non-opioid medications or immediate-release opioids) are insufficient [1] Group 2: Market Implications - The approval of this product is expected to improve medication safety while maintaining efficacy, potentially positioning the company favorably in the competitive pharmaceutical market [1]